Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense oligonucleotides targeting GRB7-S
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Antisense oligonucleotides targeting GRB7-S are synthetic oligonucleotide therapeutics designed to target and degrade the mRNA of the short isoform of Growth Factor Receptor-Bound Protein 7 (GRB7-S, characterized by exon 13 skipping) [EP100]. GRB7-S is highly expressed in early-onset gastric cancer (EOGC) tissues and is associated with poor prognosis, promoting epithelial-mesenchymal transition (EMT), cell invasion, and distant metastasis [EP100]. Mechanistically, Musashi RNA-binding protein 1 (MSI1) induces the skipping of exon 13 in GRB7 pre-mRNA, activating the Kras/PI3K/AKT/mTOR signaling pathway [EP100]. By targeting and degrading the GRB7-S transcript, these antisense oligonucleotides suppress MSI1-driven metastasis, offering a potential therapeutic strategy for early-onset gastric cancer [EP100].
- Other names
- GRB7-S ASOsGRB-7-S ASOsGRB 7-S ASOsGRB7-S antisense oligonucleotidesGRB-7-S antisense oligonucleotidesGRB 7-S antisense oligonucleotidesantisense oligonucleotides targeting the short GRB7 transcript
02
Targets
GRB7 (Growth factor receptor-bound protein 7)
Beyond the preview
Go deeper on antisense oligonucleotides targeting GRB7-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense oligonucleotides targeting GRB7-S.